Exabis Library
Welcome to the e-CCO Library!
DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP13: Artificial Intelligence (AI) in endoscopy - Deep learning for detection and scoring of Ulcerative Colitis (UC) disease activity under multiple scoring systems
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP13: Clinical and endoscopic response to ustekinumab in Crohn’s Disease: Week 16 interim analysis of the STARDUST trial
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP13: Clinical and endoscopic response to ustekinumab in Crohn’s Disease: Week 16 interim analysis of the STARDUST trial
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP13: Effect of 8 weeks of combined aerobic and resistance exercise on quality of life, muscle strength, aerobic capacity, and disease activity in patients with Inflammatory Bowel Disease; a parallel group randomized clinical trial
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP13: Immune profiling of adipose tissue in murine models of Inflammatory Bowel Disease (IBD)
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP13: Immune profiling of adipose tissue in murine models of inflammatory bowel disease (IBD)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP13: Plasma metabolite fingerprint could discriminate inflammatory bowel disease patients from healthy subjects
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP13: Plasma metabolite fingerprint could discriminate inflammatory bowel disease patients from healthy subjects
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP13: The Arborisation index: An MRI-based measure of mesenteric hyperaemia in Crohn’s Disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP14: Identification and validation of a lipidomic signature as a novel diagnostic biomarker of paediatric Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP14: Identification and validation of a lipidomic signature as a novel diagnostic biomarker of paediatric Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP14: Proctocolectomy is associated with improved transplant-free survival in patients with primary sclerosing cholangitis: results from a pooled collaborative international study
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP14: TiO2 nanoparticles abrogate the protective effect of the autoimmunity-associated PTPN22R619W variant during acute DSS colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP14: Ultra-high magnification endocytoscopy and molecular markers for defining endoscopic and histologic remission in Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP14: Validation of a new OPtical diagnosis Training platform to Improve dysplasia Characterisation in Inflammatory Bowel Disease (OPTIC-IBD): A multicentre randomised controlled study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP15 Transmural healing with vedolizumab in patients with active Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP15: An evaluation of the exposure-efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s Disease: Pharmacokinetic findings from VISIBLE 2
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
Thursday, 2 July 2020, 12:11 PM by Eloise Lanaud
DOP15: Clinical relevance of endoscopic peri-appendiceal red patch in Ulcerative Colitis patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM